3 ML cabotegravir 200 MG/ML Injection — RxCUI 2588077
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Cabotegravir: what it is, how it’s used, side effects, and interactions.
- It can actually be both, depending on the situation. If you already have HIV and your virus is under control on your current treatment, Vocabria tablets (taken with Edurant) serve...
- What exactly is Vocabria used for — is it a treatment or a prevention drug?
- This is a really important safety step. Cabotegravir on its own is not a complete HIV treatment — it only blocks one step the virus uses to replicate. If HIV somehow got into your...
- Why do I have to keep getting HIV tested if I'm using this for PrEP?
🕸️ Concept Web — How 3 ML cabotegravir 200 MG/ML Injection Connects
RxCUI 2588077 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Cabotegravir
2475077IN
-
Cabotegravir
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Apretude
2588044BN
-
Apretude
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Cabotegravir Injection
2588076SCDF -
Cabotegravir Injectable Product
2475408SCDG -
Cabotegravir Injection [Apretude]
2588079SBDF -
Apretude Injectable Product
2588046SBDG -
Injection
1649574DF -
Injectable Product
1151126DFG
-
Cabotegravir Injection
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Cabotegravir 200 MG/ML
2475407SCDC -
3 ML cabotegravir 200 MG/ML Injection [Apretude]
2588080SBD -
Cabotegravir 200 MG/ML [Apretude]
2588045SBDC
-
Cabotegravir 200 MG/ML
-
Packs 2
Fixed collections of drugs packaged and sold together, like dose packs.
🔀 Generic ⇄ Brand Crosswalk
Generic (Clinical) Concepts
-
{1 (3 ML cabotegravir 200 MG/ML Injection) / 1 (3 ML rilpivirine 300 MG/ML Injection) } Pack
GPCK · 2475415 -
Cabotegravir 200 MG/ML
SCDC · 2475407 -
Cabotegravir Injection
SCDF · 2588076 -
Cabotegravir Injectable Product
SCDG · 2475408
Brand-Name Concepts
-
3 ML cabotegravir 200 MG/ML Injection [Apretude]
SBD · 2588080 -
{1 (3 ML cabotegravir 200 MG/ML Injection) / 1 (3 ML rilpivirine 300 MG/ML Injection) } Pack [CABENUVA 600 MG / 900 MG]
BPCK · 2475416 -
Cabotegravir 200 MG/ML [Apretude]
SBDC · 2588045 -
Cabotegravir Injection [Apretude]
SBDF · 2588079 -
Apretude Injectable Product
SBDG · 2588046 -
Apretude
BN · 2588044
📦 FDA Products & Package NDCs
5 products · 5 package NDCs
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 49702-0240-15 | 1 KIT in 1 CARTON (49702-240-15) * 3 mL in 1 VIAL (49702-2... | Cabenuva | ViiV Healthcare Company | 2021-01-21 |
| 49702-0253-15 | 1 KIT in 1 CARTON (49702-253-15) * 2 mL in 1 VIAL (49702-2... | Cabenuva | ViiV Healthcare Company | 2021-01-21 |
| 49702-0264-23 | 1 KIT in 1 CARTON (49702-264-23) * 3 mL in 1 VIAL (49702-2... | Apretude | ViiV Healthcare Company | 2021-12-20 |
| 49702-0266-63 | 1 KIT in 1 CARTON (49702-266-63) * 3 mL in 1 VIAL (49702-2... | Cabenuva | ViiV Healthcare Company | 2025-01-21 |
| 49702-0280-63 | 1 KIT in 1 CARTON (49702-280-63) * 3 mL in 1 VIAL (49702-2... | Apretude | ViiV Healthcare Company | 2024-03-31 |
🧾 Billing Codes (HCPCS)
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J0741 | Inj, cabote rilpivir 2mg 3mg | 2 | CMS |
🗃️ Sources & Limits
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.